Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Proteostasis Therapeutics, Inc. (NASDAQ: PTI).

Full DD Report for PTI

You must become a subscriber to view this report.

Recent News from (NASDAQ: PTI)

Free Pre-Market Technical Recap on Axovant Sciences and Three Additional Biotech Stocks
Stock Research Monitor: BPMC, CASI, and PTI LONDON, UK / ACCESSWIRE / July 20, 2018/ If you want a free Stock Review on AXON sign up now at . Research coverage has been initiated by on Axovant Sciences Ltd (NASDAQ: AXON ), Bluepr...
Date: July, 20 2018 07:35
Translate Bio prices upsized initial public offering
Translate Bio ( TBIO ) has priced an upsized initial public offering at $13/share , the midpoint of its range. More news on: Translate Bio, Vertex Pharmaceuticals Incorporated, Galapagos, Healthcare stocks news, IPOs, Read more ...
Source: SeekingAlpha
Date: June, 27 2018 18:47
Proteostasis Added to the Russell 3000® Index
BOSTON , June 25, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein pro...
Source: PR Newswire
Date: June, 25 2018 07:00
Translate Bio Prepares For $100 Million U.S. IPO
Quick Take Translate Bio ( TBIO ) intends to sell shares of its common stock to raise $100 million from a U.S. IPO, according to an S-1/A registration statement . The firm is advancing a pipeline of mRNA-based treatment candidates to restore protein function in patients with cystic fi...
Source: SeekingAlpha
Date: June, 19 2018 13:47
Kerrisdale Capital Drills Down On A Few Shorts (Podcast)
Despite the years of bullish market activity, of headlines suggesting hedge funds are passe, and of the trend towards indexing, quant strategies, and other mechanical approaches, there still seems to be room for fundamental stock analysis and selection. Or at least, that's Kerrisdale Capital's...
Source: SeekingAlpha
Date: June, 12 2018 06:45
Your Daily Pharma Scoop: Scynexis Moves Up, Proteostasis Disappoints Investors, Cellectar Zooms
Analysis Focus: SCYX Scynexis (SCYX) is a drug manufacturer focusing on infectious diseases and has $83.85M in market capitalization. The company’s lead candidate SCY-078 is on trial for treatment of multiple serious fungal infections. Some of these fungal infections like Acute Vulv...
Source: SeekingAlpha
Date: June, 11 2018 01:50
Eloxx Pharma's ELX-02 shows encouraging action in preclinical CF studies; investors unmoved, shares down 11%
Investors appear unimpressed with preclinical data on Eloxx Pharmaceuticals' ( ELOX -10.6% ) lead candidate ELX-02 for the treatment of certain cystic fibrosis (CF) patients. The results were presented at the European Cystic Fibrosis Conference in Belgrade. More news on: Eloxx Pharmace...
Source: SeekingAlpha
Date: June, 08 2018 12:06
Today's Research Reports on Stocks to Watch: Proteostasis Therapeutics and Ophthotech Corporation
NEW YORK, NY / ACCESSWIRE / June 8, 2018 / While Proteostasis Therapeutics announced positive results from an ongoing 14-day dosing study of PTI-801, an analyst at RBC Capital Markets didn't seem impressed and downgraded the company this week as well as lowered his price target on shares. O...
Date: June, 08 2018 08:00
Analysis: Positioning to Benefit within Proteostasis Therapeutics, Yum China, Pretium Resources, Lexington Realty Trust, AngloGold Ashanti, and New Gold - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, June 08, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Proteostasis Therapeutics, Inc. (NASDAQ:PTI), Yum China Holdings Inc. (NY...
Source: GlobeNewswire
Date: June, 08 2018 07:35
Proteostasis Falls On Phase 1 Data, But Was Greatly Misunderstood
Recently, Proteostasis ( PTI ) released its phase 1 results for PTI-801 in treating patients with cystic fibrosis. This caused the stock to close lower by 38.16% to $3.03 per share. I believe that the results were misunderstood. There are still opportunities to see that the company succe...
Source: SeekingAlpha
Date: June, 08 2018 00:45


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PTI.

About Proteostasis Therapeutics, Inc. (NASDAQ: PTI)

Logo for Proteostasis Therapeutics, Inc. (NASDAQ: PTI)

Not available


Contact Information



Current Share Structure

  • Market Cap: $180,343,862 - 05/11/2018
  • Issue and Outstanding: 34,482,574 - 03/12/2018


Recent Filings from (NASDAQ: PTI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 07 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: April, 19 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 19 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 17 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 10 2018



Daily Technical Chart for (NASDAQ: PTI)

Daily Technical Chart for (NASDAQ: PTI)

Stay tuned for daily updates and more on (NASDAQ: PTI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PTI)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PTI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PTI and does not buy, sell, or trade any shares of PTI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: